First AD

Second AD

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse

Brea Lipe, MD, and Peter Forsberg, MD, review the results of the CANDOR trial evaluating DARA-Kd regimen in R/R multiple myeloma.

CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

Treatment Options for Patients with Multiple Myeloma in Early Relapse

IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

Clinical Implications of the IKEMA Trial in R/R MM

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

Treatment of Patients With MM and High-Risk Cytogenetics

Patient Profile 2: A 76-Year-Old Female with R/R MM

Selecting Patients for Treatment With DARA-Kd

Sequencing Therapies in Patients With R/R MM

Advice for Community Oncologists Treating Patients With R/R MM